Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
favezelimab + pembrolizumab + tretinoin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug is a combination of **favezelimab** (an anti-LAG-3 monoclonal antibody), **pembrolizumab** (an anti-PD-1 monoclonal antibody), and **tretinoin** (all-trans retinoic acid, a retinoid). Favezelimab and pembrolizumab work as checkpoint inhibitors to enhance antitumor immune responses: favezelimab targets **LAG-3** (lymphocyte activation gene-3) on immune cells to restore T cell function, while pembrolizumab blocks **PD-1** to prevent T cell inhibition. Tretinoin induces terminal differentiation and inhibits proliferation of malignant hemopoietic precursor cells through retinoic acid receptor (RAR) activation. This combination is under investigation for hematologic malignancies and solid tumors, though evidence for this exact three-drug combination is limited, with most data focusing on two-drug combinations.
- Other names
- All-trans retinoic acidFavezelimab/pembrolizumab
02
Targets
RARA (Retinoic acid receptor alpha)PDCD1 (Programmed cell death protein 1 receptor)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on favezelimab + pembrolizumab + tretinoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on favezelimab + pembrolizumab + tretinoin.